EP1340089B1 - Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples - Google Patents

Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples Download PDF

Info

Publication number
EP1340089B1
EP1340089B1 EP01999819A EP01999819A EP1340089B1 EP 1340089 B1 EP1340089 B1 EP 1340089B1 EP 01999819 A EP01999819 A EP 01999819A EP 01999819 A EP01999819 A EP 01999819A EP 1340089 B1 EP1340089 B1 EP 1340089B1
Authority
EP
European Patent Office
Prior art keywords
cortisol
variable
cort
conc
testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01999819A
Other languages
German (de)
French (fr)
Other versions
EP1340089A1 (en
Inventor
Peter Wanger
Lene Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagno International BV
Original Assignee
Diagno International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagno International BV filed Critical Diagno International BV
Publication of EP1340089A1 publication Critical patent/EP1340089A1/en
Application granted granted Critical
Publication of EP1340089B1 publication Critical patent/EP1340089B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Definitions

  • the present invention relates to identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples, so as to determine the function of the hypothalamic-pituitary-adrenal (HPA) axis in individual subjects.
  • HPA hypothalamic-pituitary-adrenal
  • the hypothalamus is a small, central part of the brain with several important regulatory functions, for example as regards physiologic response to external stress, body weight (especially the metabolically unfavorable abdominal obesity), the sleep-wake cycle and mood fluctuations.
  • the hypothalamus 2 is connected to the pituitary 3 as part of the central nervous system 1 and controls the secretion of different hormones from this endocrine gland.
  • ACTH adenocorticotropic hormone
  • CSH corticotropin releasing hormone
  • this will activate secretion of the stress-related hormone cortisol 6 from the cortex of the adrenal glands 5 (see reference numerals 8 and 9 in FIG 1).
  • Cortisol 6 circulates in the bloodstream and activates specific receptors, such as the glucocorticoid receptor (GR), in another small part of the brain, the hippocampus 4. This activation is indicated as 10 in FIG 1 and leads to inhibition of the release of ACTH (reference numeral 11) as well as CRH (reference numeral 12). Thus a feedback loop is established, which regulates the blood concentration of cortisol.
  • specific receptors such as the glucocorticoid receptor (GR)
  • GR glucocorticoid receptor
  • hypothalamic-pituitary-adrenal (HPA) axis constitutes an important mechanism for maintaining steady state in the human organism. Disturbances in this mechanism have been shown to lead to metabolic complications, such as increased insulin resistance and abdominal obesity. These metabolic abnormalities are associated with increased risk for cardiovascular disease, the major cause of death in industrialized countries.
  • a review of the above is found in " Neuroendocrine perturbations as a cause of insulin resistance” in Diabetes/Metabolism Research and Reviews 1999; 15:427-441, by Björntorp P . For a more detailed description see “Psychoneuroendocrine aspects on the metabolic syndrome", ISBN 91-628-3195-X, by Rosmond R., Göteborg University 1998.
  • the functional analysis of the HPA axis requires a number of cortisol measurements during the day, usually seven to ten, and may also have to be complemented by further examinations.
  • the saliva level of cortisol is strongly correlated to the level in blood serum, as reported by Aardal E. and Holm AC. in "Cortisol in saliva - reference ranges and relation to cortisol in serum” in European Journal of Clinical Chemistry and Biochemistry 1995:33(12):927-32 .
  • Test equipment for measuring the amount of saliva cortisol using Radio Immune Assays (RIA), are commercially available from Orion Diagnostica, Espoo, Finland and have been used to characterize the HPA axis in a population based study.
  • RIA Radio Immune Assays
  • Testosterone is the male sexual hormone but is present also in females, albeit in a very low concentration. This hormone interacts with cortisol in a fairly complex way, as described by Björntorp P. in "Hypothalamic origin of prevalent human disease” in “Hormones, Brain and Behaviour”, Academic Press, 2001 (in press ), which can be summarized as follows:
  • Testosterone can be measured in saliva, using the same principle as when measuring cortisol, as reported by Obminski Z and Stupnicki R in "Comparison of the testosterone-to-cortisol ratio values obtained from hormonal assays in saliva and serum” in J Sports Med Phys Fitness 1997 Mar; 37(1):50-55 , by Navarro MA et al.
  • Salivary testosterone in postmenopausal women with rheumatoid arthritis J Rheumatol 1998 Jun; 25(6):1059-62
  • Granger DA et al in "Salivary testosterone determination in studies of child health and development” in Horm Behav 1999 Feb; 35 (1):18-27 .
  • JP 2002275248 discloses a method for judging chronic stress based on saliva cortisol concentration.
  • the present invention seeks to provide a method of identifying normal and abnormal diurnal cortisol secretion patterns from human saliva samples, specifically so that the function of the HPA axis may be determined for individual subjects in a convenient and completely structured manner with high accuracy.
  • the objective is achieved through a computerized method of identifying normal and abnormal diurnal cortisol secretion patterns according to the attached independent patent claims.
  • only two measurements of saliva cortisol are performed during the same day at predetermined times.
  • the two measurement values of saliva cortisol are input to a computer program, which will interpret the values by means of a fuzzy logic algorithm.
  • the main output of the computer program is one of three possible classifications of the HPA axis function, i.e. normal, activated or blunted. The last two of these three classifications correspond to different levels of metabolic abnormalities and can be used by the tested indi-vidual as a basis for corrective measures or by physicians as a basis for therapeutic interventions.
  • the first saliva sample is used also for determination of the testosterone level, which is analyzed in a similar manner.
  • the use of the computer program according to the invention will not only for the first time allow determination of the function of the HPA axis for individual subjects rather than for an entire population; it will, moreover, provide considerable convenience, since only two saliva cortisol measurements are required for the determination of the diurnal cortisol pattern.
  • the level of testosterone which influences the evaluation of the HPA axis, can be measured simultaneously, wherein the computer program will use the measured testosterone value to further refine the evaluation of the HPA axis.
  • the invention also guarantees a structured approach, since the HPA axis function will be determined in exactly the same way in every examination. Furthermore, the computer program quantifies the degree of membership in the particular classification group by means of a group membership index, which will allow an even more detailed analysis of the function of the HPA axis, as will be described in more detail in the following.
  • the invention also involves a testosterone evaluation algorithm, advantageously implemented as part of the computer program, which evaluates the level of testosterone and integrates this information in the final determination of HPA axis abnormality.
  • a testosterone evaluation algorithm advantageously implemented as part of the computer program, which evaluates the level of testosterone and integrates this information in the final determination of HPA axis abnormality.
  • the invention will make it possible to use saliva cortisol measurements, and optionally testosterone measurements, as a diagnostic tool in health care and for prevention of disease in the general population.
  • Use of the Internet makes the test available to a large number of individuals.
  • FIGs 2a-2c illustrate typical diurnal variations in saliva cortisol concentration according to the three different main categories of HPA axis function, i.e. normal, activated and blunted, respectively.
  • the graphs illustrate typical concentration values, in nmol/dm 3 (y axis), during seven different times of the day (denoted spitl...spit7 on the x axis).
  • saliva cortisol concentration is measured at (at least) all these seven moments through the day.
  • saliva cortisol concentration is only measured at the first and second of these different times of the day, i.e. at spit1 and spit2.
  • the two measurements are made at 07.00 am and 11.00 am, as shown in FIGs 2a-2c.
  • FIG 3 illustrate a test evaluation computer 20 having a central processing unit (CPU) 21, a work memory 22 such as a random access memory (RAM), and a permanent memory 23 such as a read-only memory (ROM) and/or a hard disk (HD).
  • the test evaluation computer 20 has operative access to a database (DB) 24 for storing test results for a plurality of individuals, as will be described later with reference to an Internet use case.
  • the database 24 may be stored locally in the test evaluation computer 20 (for instance in a portion of the permanent memory 23), but it may equally well be located externally to the computer 20.
  • the computer 20 will preferably gain access to the database 24 through local connection (serial or parallel interface, infrared interface, accessory bus, etc.) or through a networked connection to a local area network (LAN) or a wide area network (WAN), such as the Internet 50.
  • local connection serial or parallel interface, infrared interface, accessory bus, etc.
  • WAN wide area network
  • the computer 20 has input means 26 as well as output means 25.
  • the input means 26 may comprise various different devices generally known per se, such as a keyboard, a mouse, or any type of digital data input interface (modem, ISDN, TCP/IP-based information exchange, etc).
  • the output means 25 may comprise various different known devices, such as a CRT display or an LCD display, a printer, or any type of digital data output interface (modem, ISDN, TCP/IP-based information exchange, etc).
  • all hardware components of the test evaluation computer 20 may be implemented by commercially available components, as is readily realized by a man skilled in the art.
  • the test evaluation computer 20 is provided with a commercially available operating system, such as the Microsoft Windows family (e.g. NT), Unix (e.g. Linux), etc.
  • test evaluation computer 20 is used as a stand-alone computer.
  • test evaluation computer 20 is used in an Internet application.
  • a step 71 the variables cort_conc_1 and cort_conc_2 are validated so as to eliminate obviously unrealistic values. If necessary, an error message is presented in a step 72, wherein the execution will terminate.
  • cort_conc_slope which is the difference between the first and second measurement variables (cort_conc_1 and cort_conc_2)
  • cort_conc_mean which is the arithmetic mean of the variables cort_conc_1 and cort_conc_2.
  • a set of three constants, alpha, beta and gamma, is predefined in the program for each of the two analysis variables, i.e. cort_conc_slope and cort_conc_mean. These constants are retrieved in a step 74.
  • Two indices which are decimal numbers between 0.00 and 1.00, are calculated in a step 75 for each variable.
  • the first index, high_ind defines to which degree the value of the variable can be regarded as high.
  • the second index, low ind similarly defines to which degree the value of the variable can be regard as low.
  • the constants are based on a survey of the scientific literature combined with information from a study population, consisting of 550 randomly selected middle-aged Swedes.
  • the constants are based on statistical correlations between the measurement values and the different types of HPA axis function. Correlations with metabolic and physiologic risk factors for heart disease were used to define the abnormalities of the HPA axis.
  • the calculated indices are stored in a step 76.
  • Each possible HPA axis is characterized by a particular combination of the calculated two indices. These combinations are defined in a basic group definition matrix: Group Cort_conc_slope Cort_conc_mean Conclusion A High High Normal HPA axis B High Low Normal HPA axis C Low High Activated HPA axis D Low Low Blunted HPA axis
  • the calculated indices from the tested individual are used to assign the individual to a particular classification group in the following way:
  • the tested subject is assigned to the group with the highest membership index in a step 79.
  • cort_conc_slope should be high and the value of cort_conc_mean may be either high or low. This appears from the leftmost portion of the graph in FIG 2a.
  • Borderline cases i.e. two classification groups with identical membership indices, may occur. These subjects are labeled as borderline normal/activated, borderline normal/blunted or borderline activated/blunted as appropriate with regard to the indices.
  • a step 80 once the program has been able to either determine a single classification group for the subject, or a borderline case as described above, the result is output through the output means 25.
  • the evaluation is refined by the addition of the information about testosterone level.
  • the testosterone value is evaluated as follows:
  • the program is adapted to evaluate whether the second cortisol concentration (cort_conc_2) is higher than the first cortisol concentration (cort_conc_1).
  • Such a situation will be labeled as inverted HPA axis and is illustrated in FIG 6. This abnormality is associated with disturbed sleep pattern and/or diurnal rhythm.
  • An embodiment of the described program is implemented using the syntax module in Statistical Package for Social Sciences (SPSS) and also using VBScript for use over the Internet.
  • SPSS Statistical Package for Social Sciences
  • the program can, however, be implemented in any other general purpose programming or scripting language, including but not limited to C++, Java, Visual Basic, Delphi or JavaScript.
  • the classifications were also compared to known risk factors for heart disease and significant associations were observed.
  • One example is insulin resistance (s-insulin/s-glucose quotient) in males, which was higher in the groups with abnormal HPA axis. Hence, the method apparently identifies individuals with rather discrete deviations from normality.
  • the evaluation is further refined by the addition of the information about testosterone levels. This results in a doubling of the number of groups, since the testosterone value may be either normal or abnormal, i.e. abnormal when high in women or low in men, and otherwise normal.
  • the invention allows determination of the functional state of the HPA axis, based on only two measurements of the concentration of cortisol in saliva, performed the same day at defined times, optionally in addition to one simultaneously performed measurement of testosterone level in saliva.
  • a computer program performs the interpretation of the test results.
  • the invention facilitates practical use of measurements of saliva cortisol for determination of the function of the HPA axis, since only two saliva tests are needed from each subject.
  • the use of a computer program for evaluation of the measurement values guarantees that all subjects are evaluated in an identical way in all examinations.
  • the derangements in HPA axis function, identified by the program are relevant for the health of individual subjects, and the computer-based analysis of the measurement values gives new information, hitherto not available. Use over the Internet provides access to the system to a large number of individuals.
  • the addition of testosterone values improves the relationship between the diagnostic groups and risk factors for e.g. cardiovascular disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Normal and abnormal diurnal cortisol secretion patterns are identified from human saliva samples by an in vitro method. First and second saliva samples are taken from one human individual at first and second predetermined times during the same day. A first cortisol concentration is determined in the first saliva sample, and a second cortisol concentration is determined in the second saliva sample. An abnormal secretion pattern is then compared to a normal secretion pattern with the help of a fuzzy logic algorithm. A function of the hypothalamic-pituitary-adrenal (HPA) axis is then determined for the human individual. Optionally, a testosterone level is determined from one of the samples and is used in combination with the cortisol concentrations to provide a redefined determination.

Description

    Technical Field
  • The present invention relates to identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples, so as to determine the function of the hypothalamic-pituitary-adrenal (HPA) axis in individual subjects.
  • Background Art
  • The hypothalamus is a small, central part of the brain with several important regulatory functions, for example as regards physiologic response to external stress, body weight (especially the metabolically unfavorable abdominal obesity), the sleep-wake cycle and mood fluctuations. As shown in FIG 1, the hypothalamus 2 is connected to the pituitary 3 as part of the central nervous system 1 and controls the secretion of different hormones from this endocrine gland. One of these hormones is ACTH (adenocorticotropic hormone), the secretion of which is activated through secretion of corticotropin releasing hormone (CRH) from the hypothalamus 2, as indicated by reference numeral 7 in FIG 1. In response, this will activate secretion of the stress-related hormone cortisol 6 from the cortex of the adrenal glands 5 (see reference numerals 8 and 9 in FIG 1).
  • Cortisol 6 circulates in the bloodstream and activates specific receptors, such as the glucocorticoid receptor (GR), in another small part of the brain, the hippocampus 4. This activation is indicated as 10 in FIG 1 and leads to inhibition of the release of ACTH (reference numeral 11) as well as CRH (reference numeral 12). Thus a feedback loop is established, which regulates the blood concentration of cortisol.
  • The joint operation of the above functions, in the medical literature commonly referred to as the hypothalamic-pituitary-adrenal (HPA) axis, constitutes an important mechanism for maintaining steady state in the human organism. Disturbances in this mechanism have been shown to lead to metabolic complications, such as increased insulin resistance and abdominal obesity. These metabolic abnormalities are associated with increased risk for cardiovascular disease, the major cause of death in industrialized countries. A review of the above is found in "Neuroendocrine perturbations as a cause of insulin resistance" in Diabetes/Metabolism Research and Reviews 1999; 15:427-441, by Björntorp P. For a more detailed description see "Psychoneuroendocrine aspects on the metabolic syndrome", ISBN 91-628-3195-X, by Rosmond R., Göteborg University 1998.
  • Abnormal concentrations of cortisol have also been shown to be the biochemical mechanism for the influence of external stress factors on the metabolic system, which lead to increased risk for heart disease, in both humans and experimental animals.
  • Since the concentration of this hormone in blood serum shows diurnal variation, the functional analysis of the HPA axis requires a number of cortisol measurements during the day, usually seven to ten, and may also have to be complemented by further examinations.
  • The saliva level of cortisol is strongly correlated to the level in blood serum, as reported by Aardal E. and Holm AC. in "Cortisol in saliva - reference ranges and relation to cortisol in serum" in European Journal of Clinical Chemistry and Biochemistry 1995:33(12):927-32. Test equipment for measuring the amount of saliva cortisol, using Radio Immune Assays (RIA), are commercially available from Orion Diagnostica, Espoo, Finland and have been used to characterize the HPA axis in a population based study. However, the identification of abnormalities has up to now only been possible by means of statistical analysis of groups of subjects. Due to the large inter- and intra-individual variability, it has hitherto not been possible to classify individual subjects.
  • Testosterone is the male sexual hormone but is present also in females, albeit in a very low concentration. This hormone interacts with cortisol in a fairly complex way, as described by Björntorp P. in "Hypothalamic origin of prevalent human disease" in "Hormones, Brain and Behaviour", Academic Press, 2001 (in press), which can be summarized as follows:
    1. 1. In males low testosterone implies a more negative response to cortisol alteration, compared to the average or intermediate testosterone level. However, a high testosterone level also implies negative effects. Therefore, three levels of testosterone have to be defined, i.e. low, normal/intermediate and high. In males the gonads, i.e. the testicles, secrete most of the testosterone.
    2. 2. In females testosterone levels are normally low, i.e. testosterone may be close to zero without identifiable negative effects. However, testosterone levels in the upper quartile in a normal population are associated with increased risk for cardiovascular disease, and this relationship is stronger when cortisol levels are abnormal. It is assumed that the testosterone in females is secreted by the adrenal cortex, as is cortisol.
  • In a recent study by Shifren JL, Braunstein GD, Simon JA, et al., "Transdermal testosterone treatment in women with impaired sexual function after oophorectomy", N Engl J Med (United States), Sept 2000, 343(10) p 682-8, it was found that a certain (very low) level of testosterone may be necessary also for women, in order to maintain general well-being and a satisfying sex life.
  • Testosterone can be measured in saliva, using the same principle as when measuring cortisol, as reported by Obminski Z and Stupnicki R in "Comparison of the testosterone-to-cortisol ratio values obtained from hormonal assays in saliva and serum" in J Sports Med Phys Fitness 1997 Mar; 37(1):50-55, by Navarro MA et al. In "Salivary testosterone in postmenopausal women with rheumatoid arthritis", J Rheumatol 1998 Jun; 25(6):1059-62 and by Granger DA et al in "Salivary testosterone determination in studies of child health and development" in Horm Behav 1999 Feb; 35 (1):18-27.
  • JP 2002275248 discloses a method for judging chronic stress based on saliva cortisol concentration.
  • Raff et al., "Late-night salivary cortisol as a screening test for Cushing's syndrome," Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 8, pp. 2681-2685, 1998, discloses a method for screening patients for spontaneous Cushing's syndrome based on measurement of late-night salivary cortisol.
  • Rosmond et al., "Stress-related cortisol secretion in men: Relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities," Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 6, pp. 1853-1859, 1998, discloses relations between stress and salivary cortisol concentrations.
  • Summary of the Invention
  • In view of the above shortcomings in the prior art, the present invention seeks to provide a method of identifying normal and abnormal diurnal cortisol secretion patterns from human saliva samples, specifically so that the function of the HPA axis may be determined for individual subjects in a convenient and completely structured manner with high accuracy.
  • The objective is achieved through a computerized method of identifying normal and abnormal diurnal cortisol secretion patterns according to the attached independent patent claims. According to a preferred embodiment, only two measurements of saliva cortisol, compared to seven to ten measurements in the prior art, are performed during the same day at predetermined times. The two measurement values of saliva cortisol are input to a computer program, which will interpret the values by means of a fuzzy logic algorithm. The main output of the computer program is one of three possible classifications of the HPA axis function, i.e. normal, activated or blunted. The last two of these three classifications correspond to different levels of metabolic abnormalities and can be used by the tested indi-vidual as a basis for corrective measures or by physicians as a basis for therapeutic interventions.
  • Advantageously, the first saliva sample is used also for determination of the testosterone level, which is analyzed in a similar manner.
  • The use of the computer program according to the invention will not only for the first time allow determination of the function of the HPA axis for individual subjects rather than for an entire population; it will, moreover, provide considerable convenience, since only two saliva cortisol measurements are required for the determination of the diurnal cortisol pattern. In addition, the level of testosterone, which influences the evaluation of the HPA axis, can be measured simultaneously, wherein the computer program will use the measured testosterone value to further refine the evaluation of the HPA axis.
  • The invention also guarantees a structured approach, since the HPA axis function will be determined in exactly the same way in every examination. Furthermore, the computer program quantifies the degree of membership in the particular classification group by means of a group membership index, which will allow an even more detailed analysis of the function of the HPA axis, as will be described in more detail in the following.
  • Other objects, features and advantages of the present invention will appear from the following detailed disclosure, from the appended drawings as well as from the subclaims.
  • Brief Description of the Drawings
  • A preferred embodiment and various other aspects of the present invention will now be described in more detail, reference being made to the accompanying drawings, in which:
    • FIG 1 is a schematic illustration of the hypothalamic-pituitary-adrenal (HPA) axis,
    • FIGs 2a-2c are graphical representations of diurnal cortisol variation according to three different main categories of HPA axis function,
    • FIG 3 is a schematic overview of a computer system environment in which the computer program according to the invention may be executed, when used in an Internet application,
    • FIG 4 is a flowchart of the main steps of the method according to a preferred embodiment,
    • FIG 5 is a flowchart of an Internet use case for remote test and evaluation of diurnal cortisol secretion patterns from human saliva samples, and
    • FIG 6 is a graphical representation of a diurnal cortisol variation known as inverted HPA axis function.
    Detailed Disclosure of the Invention
  • As will be described in detail in the following, the main features of the invention involve:
    1. 1. The use of only two measurements of saliva cortisol concentration, sampled at defined times the same day.
    2. 2. A cortisol analysis algorithm, preferably implemented as a computer program, which analyses the measurement values and evaluates if the HPA axis function is normal or abnormal. If the HPA axis is abnormal, the program may also determine the type of abnormality.
    3. 3. Use of the above-mentioned computer program for remote distribution of tests and test results over the Internet.
  • Preferably, the invention also involves a testosterone evaluation algorithm, advantageously implemented as part of the computer program, which evaluates the level of testosterone and integrates this information in the final determination of HPA axis abnormality.
  • As stated above, the invention will make it possible to use saliva cortisol measurements, and optionally testosterone measurements, as a diagnostic tool in health care and for prevention of disease in the general population. Use of the Internet makes the test available to a large number of individuals.
  • FIGs 2a-2c illustrate typical diurnal variations in saliva cortisol concentration according to the three different main categories of HPA axis function, i.e. normal, activated and blunted, respectively. The graphs illustrate typical concentration values, in nmol/dm3 (y axis), during seven different times of the day (denoted spitl...spit7 on the x axis). Conventionally, as mentioned above, saliva cortisol concentration is measured at (at least) all these seven moments through the day. According to the invention, on the other hand, saliva cortisol concentration is only measured at the first and second of these different times of the day, i.e. at spit1 and spit2. Preferably, the two measurements are made at 07.00 am and 11.00 am, as shown in FIGs 2a-2c.
  • The test procedure will now be described with reference to FIGs 3 and 4. FIG 3 illustrate a test evaluation computer 20 having a central processing unit (CPU) 21, a work memory 22 such as a random access memory (RAM), and a permanent memory 23 such as a read-only memory (ROM) and/or a hard disk (HD). The test evaluation computer 20 has operative access to a database (DB) 24 for storing test results for a plurality of individuals, as will be described later with reference to an Internet use case. The database 24 may be stored locally in the test evaluation computer 20 (for instance in a portion of the permanent memory 23), but it may equally well be located externally to the computer 20. In the latter case, the computer 20 will preferably gain access to the database 24 through local connection (serial or parallel interface, infrared interface, accessory bus, etc.) or through a networked connection to a local area network (LAN) or a wide area network (WAN), such as the Internet 50.
  • Additionally, the computer 20 has input means 26 as well as output means 25. The input means 26 may comprise various different devices generally known per se, such as a keyboard, a mouse, or any type of digital data input interface (modem, ISDN, TCP/IP-based information exchange, etc). Correspondingly, the output means 25 may comprise various different known devices, such as a CRT display or an LCD display, a printer, or any type of digital data output interface (modem, ISDN, TCP/IP-based information exchange, etc). Generally, all hardware components of the test evaluation computer 20 may be implemented by commercially available components, as is readily realized by a man skilled in the art. Moreover, the test evaluation computer 20 is provided with a commercially available operating system, such as the Microsoft Windows family (e.g. NT), Unix (e.g. Linux), etc.
  • Next, with particular reference to FIG 4 a presently preferred embodiment of the test procedure will be described, where the test evaluation computer 20 is used as a stand-alone computer. Another embodiment, where the test evaluation computer 20 is used in an Internet application, will follow later.
  • Test procedure
    1. 1. Saliva from the tested subject is obtained at 07.00 and 11.00, as indicated in FIGs 2a-2c, using conventional technique.
    2. 2. The cortisol concentrations in the two test samples are measured in a conventional analysis machine, for instance one based on the above-mentioned RIA technique.
    3. 3. The testosterone level is determined for one of the saliva samples, preferably the first sample (07.00), using the same basic principle (for instance RIA technique) as when determining the cortisol concentrations.
    4. 4. The first and second measurement values are entered into the working memory 22 of the computer 20 through its input means 26 (step 70 in FIG 4). This may be performed either automatically using electronic communication between the analysis machine and the computer, or manually by the laboratory personnel using e.g. a keyboard and/or a mouse. Alternatively, particularly in an Internet application, the measurement values may be read from the test database 24.
    5. 5. The permanent memory 23 is provided with a computer program comprising program code adapted to be read into the working memory 22 and executed by the processor 21 so as to perform the following test evaluation algorithm in an ordered sequence of operations and calculations:
      • First, in step 70, two measurement variables, cort_conc_1 and cort_conc_2, are formed from the first and second measurement values, respectively.
  • Then, in a step 71 the variables cort_conc_1 and cort_conc_2 are validated so as to eliminate obviously unrealistic values. If necessary, an error message is presented in a step 72, wherein the execution will terminate.
  • Otherwise, in a step 73 the program calculates two analysis variables, namely cort_conc_slope, which is the difference between the first and second measurement variables (cort_conc_1 and cort_conc_2), and cort_conc_mean, which is the arithmetic mean of the variables cort_conc_1 and cort_conc_2.
  • A set of three constants, alpha, beta and gamma, is predefined in the program for each of the two analysis variables, i.e. cort_conc_slope and cort_conc_mean. These constants are retrieved in a step 74.
  • Two indices, which are decimal numbers between 0.00 and 1.00, are calculated in a step 75 for each variable. The first index, high_ind, defines to which degree the value of the variable can be regarded as high. The second index, low ind, similarly defines to which degree the value of the variable can be regard as low. Preferably, it is calculated as the complement of high_ind (i.e., low_ind=1-high_ind). These index calculations are based on the three above-mentioned constants, alpha, beta and gamma, for each indexed variable. The values of these constants have been empirically derived before execution of the program. In one implementation made by the inventors the constants are based on a survey of the scientific literature combined with information from a study population, consisting of 550 randomly selected middle-aged Swedes. The constants are based on statistical correlations between the measurement values and the different types of HPA axis function. Correlations with metabolic and physiologic risk factors for heart disease were used to define the abnormalities of the HPA axis.
  • The constants, alpha, beta and gamma, are used in the following way in step 75 when calculating the first index, high_ind, for each of the variables:
    • If the variable's value is lower than (or equal to) constant alpha, the index is set to 0.00.
    • If the variable's is larger than (or equal to) constant gamma, the index is set to 1.00.
    • If the variable's value is larger than constant alpha and smaller than (or equal to) constant beta, a program function calculates an index between 0.00 and 0.50. More specifically, the index is set to 2*(((x - alpha) / (gamma - alpha))2), where x is the value of the variable.
    • If the variable's value is larger than (or equal to) constant beta and smaller than constant gamma, a program function calculates an index between 0.50 and 1.00. More specifically, the index is set to 1 - (2* (((x - gamma) / (x - alpha))2)), where x is the value of the variable.
  • The calculated indices are stored in a step 76.
  • Each possible HPA axis is characterized by a particular combination of the calculated two indices. These combinations are defined in a basic group definition matrix:
    Group Cort_conc_slope Cort_conc_mean Conclusion
    A High High Normal HPA axis
    B High Low Normal HPA axis
    C Low High Activated HPA axis
    D Low Low Blunted HPA axis
  • This matrix has four possible categories, labeled A-D. Categories A and B = normal HPA axis, category C = activated HPA axis, and category D = blunted HPA axis. The calculated indices from the tested individual are used to assign the individual to a particular classification group in the following way:
    • A membership index is calculated for each classification group, as defined in the above table, by retrieving the lowest index value in the corresponding column of the group definition matrix, as shown in a step 77. Thus, for each group (A-D) the membership index is defined as min (index_for_cort_conc_slope, index_for_cort_conc_mean). This minimum value is stored in a step 78.
  • Then, the tested subject is assigned to the group with the highest membership index in a step 79.
  • The above may be exemplified as follows:
  • Example
  • In a normal subject, the value of cort_conc_slope should be high and the value of cort_conc_mean may be either high or low. This appears from the leftmost portion of the graph in FIG 2a.
  • The corresponding indices for a subject could then be as follows:
    • The high_index for cort_conc_slope might be 1.00 (corresponds to a high test value in the morning sample at 07.00 am and a low test value in the second sample at 11.00).
    • The high_ind for cort_conc_mean might be 0.6.
    • This subject belongs to the group with normal HPA axis (group A in the group definition matrix) with a membership value of 0.6 (i.e. the minimum of 1.00 and 0.6). The membership value of any other group would be less than this value.
  • Borderline cases, i.e. two classification groups with identical membership indices, may occur. These subjects are labeled as borderline normal/activated, borderline normal/blunted or borderline activated/blunted as appropriate with regard to the indices.
  • In a step 80, once the program has been able to either determine a single classification group for the subject, or a borderline case as described above, the result is output through the output means 25.
  • The evaluation is refined by the addition of the information about testosterone level. The testosterone value is evaluated as follows:
    1. 1. In males: If the value is below a threshold value, the level is labeled as low. If the value is above this threshold value, the level is labeled normal.
    2. 2. In females: If the testosterone value is above a threshold value it is labeled high, otherwise it is labeled normal.
  • Advantageously, the program is adapted to evaluate whether the second cortisol concentration (cort_conc_2) is higher than the first cortisol concentration (cort_conc_1). Such a situation will be labeled as inverted HPA axis and is illustrated in FIG 6. This abnormality is associated with disturbed sleep pattern and/or diurnal rhythm.
  • Program implementation
  • An embodiment of the described program is implemented using the syntax module in Statistical Package for Social Sciences (SPSS) and also using VBScript for use over the Internet. The program can, however, be implemented in any other general purpose programming or scripting language, including but not limited to C++, Java, Visual Basic, Delphi or JavaScript.
  • Program validation
  • Program output has been compared to actual measurement values (seven each day) from the study population mentioned above. The program clearly identified the three main types of HPA axis diurnal pattern, see FIGs 2a-2c, using only two of the saliva cortisol measurements (at 07.00 am and 11.00 am).
  • The classifications (in three main categories) have been compared to the outcomes of associated tests regarding saliva cortisol. These tests are:
    1. 1. Response to a standardized lunch. Food induces an increase in blood and saliva cortisol. This increase can be measured by repeated tests and used as an aid in the determination of the function of the HPA axis in a particular individual.
    2. 2. Dexamethason suppression test. Dexamethason is a synthetic substance, essentially identical with the cortisol, secreted from the adrenal glands. When dexamethason is administered in the form of pills, the blood and saliva cortisol is decreased. The rate of decrease can be measured by repeated tests and used as an aid in the determination of the function of the HPA axis in a particular individual.
  • The correlations between the results from these two associated tests and the classification performed by the computer program were very good, indicating that the same information was established using the program's analysis of only two tests compared to the conventional method, using statistical analysis of seven tests.
  • The classifications (in three main categories) were also compared to known risk factors for heart disease and significant associations were observed. One example is insulin resistance (s-insulin/s-glucose quotient) in males, which was higher in the groups with abnormal HPA axis. Hence, the method apparently identifies individuals with rather discrete deviations from normality.
  • The evaluation is further refined by the addition of the information about testosterone levels. This results in a doubling of the number of groups, since the testosterone value may be either normal or abnormal, i.e. abnormal when high in women or low in men, and otherwise normal.
  • Advantages
  • The invention allows determination of the functional state of the HPA axis, based on only two measurements of the concentration of cortisol in saliva, performed the same day at defined times, optionally in addition to one simultaneously performed measurement of testosterone level in saliva. A computer program performs the interpretation of the test results. The invention facilitates practical use of measurements of saliva cortisol for determination of the function of the HPA axis, since only two saliva tests are needed from each subject. The use of a computer program for evaluation of the measurement values guarantees that all subjects are evaluated in an identical way in all examinations. The derangements in HPA axis function, identified by the program, are relevant for the health of individual subjects, and the computer-based analysis of the measurement values gives new information, hitherto not available. Use over the Internet provides access to the system to a large number of individuals. The addition of testosterone values improves the relationship between the diagnostic groups and risk factors for e.g. cardiovascular disease.
  • The present invention has been described above with reference to a preferred embodiment. However, other embodiments than the one disclosed above are equally possible within the scope of the invention, as defined by the attached independent patent claims.

Claims (6)

  1. An in vitro method at identification of normal and abnormal diurnal cortisol secretion patterns from human saliva samples, wherein first and second saliva samples are taken from a human individual at first and second predefined times during the same day, a first cortisol concentration is determined in the first saliva sample, and a second cortisol concentration is determined in the second saliva sample, comprising:
    providing first and second variables (cort_conc_slope, cort_conc_mean) ;
    assigning values to the first and second variables which are associated with the determined first and second cortisol concentrations, wherein the first variable (cort_conc_slope) is calculated as a difference between the determined first and second cortisol concentrations, and wherein the second variable (cort conc mean) is calculated as an arithmetic mean of the determined first and second cortisol concentrations;
    providing a set of three predefined constants (alpha, beta, gamma) for each variable;
    calculating, for each of the first and the second variables (cort_conc_slope, cort_conc_mean), a first fuzzy logic index (high_ind) to represent a degree to which the variable has a high value in relation to the predefined constants, wherein the first fuzzy logic index (high_ind) is set to:
    0.0, if the variable is smaller than or equal to a first constant (alpha) in the set of predefined constants;
    1.0, if the variable is larger than or equal to a third constant (gamma) in the set of predefined constants;
    a value between 0.0 and 0.5, if the variable is larger than the first constant (alpha) and smaller than or equal to a second constant (beta) in the set of predefined constants;
    a value between 0.5 and 1.0, if the variable is larger than the second constant (beta) and smaller than the third constant (gamma);
    calculating, for each variable, a second fuzzy logic index (low_ind) as a complement of the first fuzzy logic index (high_ind) to represent a degree to which the variable has a low value in relation to the predefined constants;
    matching different combinations of the first and second fuzzy logic indices, as calculated for the first and second variables, with predetermined definitions of a normal diurnal cortisol secretion pattern and at least one abnormal diurnal cortisol secretion pattern; and
    selecting the definition where the best correspondence occurs;
    evaluating a level of testosterone in at least one of said first and second saliva samples, and
    using the result of the testosterone evaluation for determining a function of a hypothalamic-pituitary-adrenal axis for said human individual in response to the selected diurnal cortisol secretion pattern definition.
  2. A method according to claim 1, wherein the difference between said first and second predefined times during the same day is 4 hours.
  3. A method according to claim 2, wherein said first predefined time is at 07.00 am and said second predefined time is at 11.00 am during the same day.
  4. A computer program product directly loadable into an internal memory (22) of a computer (20), comprising program code for performing the steps of any one of claims 1-3 when executed on said computer.
  5. A computer program product according to claim 4, embodied on a computer-readable medium (23).
  6. A computer having a memory (22) and a processor (21), the memory containing program code for performing the steps of any one of clams 1-3 when executed by said processor.
EP01999819A 2000-12-04 2001-12-04 Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples Expired - Lifetime EP1340089B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004461 2000-12-04
SE0004461A SE517528C2 (en) 2000-12-04 2000-12-04 Computerized identification of normal and abnormal daily patterns for cortisol secretion and testosterone levels from human saliva samples
PCT/SE2001/002670 WO2002046771A1 (en) 2000-12-04 2001-12-04 Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples

Publications (2)

Publication Number Publication Date
EP1340089A1 EP1340089A1 (en) 2003-09-03
EP1340089B1 true EP1340089B1 (en) 2007-08-15

Family

ID=20282077

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01999819A Expired - Lifetime EP1340089B1 (en) 2000-12-04 2001-12-04 Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples

Country Status (7)

Country Link
US (1) US7805396B2 (en)
EP (1) EP1340089B1 (en)
JP (1) JP2004515765A (en)
AT (1) ATE370417T1 (en)
DE (1) DE60130020T2 (en)
SE (1) SE517528C2 (en)
WO (1) WO2002046771A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060129590A1 (en) * 2004-12-10 2006-06-15 Aoki-Rice Companies Method and medium for managing data
CA2684797C (en) 2007-05-10 2015-01-06 Advanced Breath Diagnostics, Llc Methods and systems for assessing gastric emptying
KR101029251B1 (en) 2009-06-18 2011-04-18 전남대학교산학협력단 Evaluation Method and Evaluation Indicator of Cortisol Diurnal Rhythm by Determination of Salivary Cortisol
US11195057B2 (en) 2014-03-18 2021-12-07 Z Advanced Computing, Inc. System and method for extremely efficient image and pattern recognition and artificial intelligence platform
US8311973B1 (en) 2011-09-24 2012-11-13 Zadeh Lotfi A Methods and systems for applications for Z-numbers
US11914674B2 (en) 2011-09-24 2024-02-27 Z Advanced Computing, Inc. System and method for extremely efficient image and pattern recognition and artificial intelligence platform
US8873813B2 (en) 2012-09-17 2014-10-28 Z Advanced Computing, Inc. Application of Z-webs and Z-factors to analytics, search engine, learning, recognition, natural language, and other utilities
US11074495B2 (en) 2013-02-28 2021-07-27 Z Advanced Computing, Inc. (Zac) System and method for extremely efficient image and pattern recognition and artificial intelligence platform
US9916538B2 (en) 2012-09-15 2018-03-13 Z Advanced Computing, Inc. Method and system for feature detection
KR101444235B1 (en) * 2012-07-17 2014-09-26 주식회사 피코팜 A Diagnosis Method of Complex Regional Pain Syndrome Type 1 Using Correlation of Hypothalamic pituitary adrenal axis function
US10772534B2 (en) 2013-03-13 2020-09-15 Advanced Breath Diagnostics, Llc Single-point gastric emptying breath tests
KR102404986B1 (en) * 2022-01-20 2022-06-07 (주) 마인즈에이아이 A Method for providing information for an andropause diagnosis and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788640A (en) * 1995-10-26 1998-08-04 Peters; Robert Mitchell System and method for performing fuzzy cluster classification of stress tests
EP1027459A1 (en) * 1997-07-14 2000-08-16 Abbott Laboratories Telemedicine
JPH1138004A (en) * 1997-07-16 1999-02-12 Pola Chem Ind Inc Quantifying method for stress
JP3108765B2 (en) * 1999-03-24 2000-11-13 工業技術院長 Chronic stress determination method and device, recording medium, determination sheet

Also Published As

Publication number Publication date
SE0004461D0 (en) 2000-12-04
US20040039719A1 (en) 2004-02-26
WO2002046771A1 (en) 2002-06-13
EP1340089A1 (en) 2003-09-03
SE0004461L (en) 2002-06-05
ATE370417T1 (en) 2007-09-15
SE517528C2 (en) 2002-06-18
DE60130020T2 (en) 2008-05-08
DE60130020D1 (en) 2007-09-27
US7805396B2 (en) 2010-09-28
US20100241606A9 (en) 2010-09-23
JP2004515765A (en) 2004-05-27

Similar Documents

Publication Publication Date Title
EP1340089B1 (en) Computerized identification of normal and abnormal diurnal cortisol secretion patterns and levels of testosterone from human saliva samples
Randolph Jr et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition
Young et al. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women
Sowers et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity
Politi et al. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis
US7647234B1 (en) Cardiovascular healthcare management system and method
US20030125609A1 (en) Method for reliable measurement in medical care and patient self monitoring
Hlatky et al. Tying clinical research to patient care by use of an observational database
CN111223571A (en) Adverse drug reaction monitoring method and device, computer equipment and storage medium
Guyatt et al. Moving from evidence to action
Nishioka et al. Incidence and seasonality of type 1 diabetes: a population-based 3-year cohort study using the National Database in Japan
Mollard et al. Emerging evidence on the link between depressive symptoms and bone loss in postmenopausal women
Wachtel et al. Creation and verification of reference intervals
Huang et al. Correlation between menopausal symptoms and everyday cognition in Chinese (peri) menopausal women
Jørgensen et al. Plasma glucose reference intervalin a low-risk population. 2. Impact ofthe new WHO and ADA recommendations on the diagnosis of diabetes mellitus
Garcia-Alfaro et al. Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status
Christensen et al. Masculinising testosterone treatment and effects on preclinical cardiovascular disease, muscle strength and power, aggression, physical fitness and respiratory function in transgender men: protocol for a 10-year, prospective, observational cohort study in Denmark at the Body Identity Clinic (BIC)
CN115620900B (en) System and method for screening polycystic ovary syndrome
US20070038037A1 (en) Method and apparatus for symptom-based order protocoling within the exam ordering process
Raff et al. Cosyntropin-stimulated salivary cortisol in hospitalized patients with hypoproteinemia
US20200000413A1 (en) Method and system for automated diagnostics of none-infectious illnesses
Frank et al. Adolescent BMI trajectory and associations with adult metabolic syndrome and offspring obesity
JP2003526137A (en) Method and apparatus for automatically allocating staffing
Michaelidou et al. Recalibration of thinking about adrenocortical function assessment: how the ‘random’cortisol relates to the short synacthen test results
Sarasin Decision analysis and its application in clinical medicine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17P Request for examination filed

Effective date: 20030630

17Q First examination report despatched

Effective date: 20050411

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/74 20060101AFI20070205BHEP

Ipc: G06N 7/02 20060101ALI20070205BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60130020

Country of ref document: DE

Date of ref document: 20070927

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071126

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070815

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071116

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080115

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071115

26N No opposition filed

Effective date: 20080516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20141222

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20141222

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20151230

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151231

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20160101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160101

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161231

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181220

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20181214

Year of fee payment: 18

Ref country code: GB

Payment date: 20181217

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60130020

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191204

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200701